Sellas Life Sciences Q3 Net Loss Widens 49% to $10.09 Million

PUBT · 2d ago
Sellas Life Sciences Q3 Net Loss Widens 49% to $10.09 Million
  • Sellas Life Sciences’ third-quarter 2026 net loss widened 49% year over year to $10.09 million.
  • Research and development expenses rose 67% to $7.03 million, due to higher manufacturing, consulting and clinical trial costs.
  • Cash and cash equivalents totaled $134.71 million at September 30, 2026.
  • Topline primary endpoint results from the Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia are expected in November 2026.
  • The Phase 2 SLS009 trial in newly diagnosed AML enrolled 40 patients, with preliminary topline data expected in fourth-quarter 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121605PRIMZONEFULLFEED9876791) on November 12, 2026, and is solely responsible for the information contained therein.